版本:
中国

BRIEF-Aurinia Pharma announces 48-week results from study of voclosporin

March 27 Aurinia Pharmaceuticals Inc:

* Aurinia Pharmaceuticals-announces 48-week results from “Aurinia early urinary protein reduction predicts response study” of voclosporin for treatment of lupus nephritis

* Aurinia Pharmaceuticals Inc says study successfully achieved primary objective - SEC filing

* Aurinia Pharmaceuticals says no new safety signals were observed with use of voclosporin in ln patients; voclosporin was well-tolerated Source text: (bit.ly/2mHvT4L) Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐